CULLINAN THERAPEUTICS INC. - COMMON STOCK

Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer

15 Aug 2022 13:57:42 By Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2022 Financial Results

10 Aug 2022 04:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Aug 2022 13:55:00 By Nasdaq GlobeNewswire

Cullinan Oncology to Participate in William Blair Biotech Focus Conference

05 Jul 2022 13:01:00 By Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Jul 2022 13:38:19 By Nasdaq GlobeNewswire

Cullinan Oncology and Taiho Pharmaceutical Complete Agreement for Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417

23 Jun 2022 05:00:01 By Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01 Jun 2022 14:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology to Present Updated Data Demonstrating the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting

31 May 2022 05:00:01 By Nasdaq GlobeNewswire

Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting

26 May 2022 05:45:00 By Nasdaq GlobeNewswire

Cullinan Oncology to Present at H.C. Wainwright Global Investment Conference

19 May 2022 05:00:01 By Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports First Quarter 2022 Financial Results

16 May 2022 03:45:00 By Nasdaq GlobeNewswire

Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl

11 May 2022 23:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

02 May 2022 14:10:24 By Nasdaq GlobeNewswire

Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting

27 Apr 2022 07:00:00 By Nasdaq GlobeNewswire

Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences

05 Apr 2022 05:00:01 By Nasdaq GlobeNewswire

Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 Apr 2022 13:34:22 By Nasdaq GlobeNewswire

Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients

28 Mar 2022 13:01:00 By Nasdaq GlobeNewswire

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

17 Mar 2022 04:08:06 By Nasdaq GlobeNewswire

Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022

17 Mar 2022 04:00:01 By Nasdaq GlobeNewswire

Cullinan Oncology to Present at the Barclays Global Healthcare Conference

09 Mar 2022 05:00:02 By Nasdaq GlobeNewswire